Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrasonography Doppler Assessment of Peripheral Enthesitis in Spondyloarthropathies Treated With Infliximab
2006-001579-40Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of infliximab in spondyloarthritis (SpA), ankylosing spondylitis (AS) and enthesitis, sponsored by Merck & Co. Primary endpoint: Number of enthesitis between Week 4 and Week 12 evaluated using PDUS and IODP software. Started Mar 2007; status: terminated.
02
Drugs
infliximab
03
Conditions
spondyloarthritis (SpA)ankylosing spondylitis (AS)enthesitis
Beyond the preview
Go deeper on 2006-001579-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001579-40.